
1. Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 
2021 Oct 19.

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with
multiple myeloma.

Aleman A(1), Upadhyaya B(2), Tuballes K(3), Kappes K(2), Gleason CR(4), Beach
K(4), Agte S(2), Srivastava K(4); PVI/Seronet Study Group, Van Oekelen O(1),
Barcessat V(3), Bhardwaj N(5), Kim-Schulze S(6), Gnjatic S(7), Brown B(8),
Cordon-Cardo C(9), Krammer F(4), Merad M(10), Jagannath S(2), Wajnberg A(11),
Simon V(12), Parekh S(13).

Collaborators: Andre D, Azad A, Banu R, Bermúdez-González MC, Cai G, Cognigni C, 
David K, Floda D, Firpo A, Kleiner G, Lyttle N, Mendez W, Mulder LCF, Mendu R,
Oostenink A, Rooker A, Russo K, Salimbangon A, Saksena M, Shin A, Sominsky L.

Author information: 
(1)Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount
Sinai, New York, NY, USA; Department of Medicine, Hematology and Medical
Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch
Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
(2)Department of Medicine, Hematology and Medical Oncology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School 
of Medicine at Mount Sinai, New York, NY, USA.
(3)Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New
York, NY, USA.
(4)Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York,
NY, USA; Department of Pathology, Molecular and Cell-based Medicine, Icahn School
of Medicine at Mount Sinai, New York, NY, USA.
(5)Department of Medicine, Hematology and Medical Oncology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School 
of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of
Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
(6)Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount 
Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, New York, NY, USA.
(7)Department of Medicine, Hematology and Medical Oncology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School 
of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of
Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount
Sinai, New York, NY, USA; Human Immune Monitoring Center, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences,
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
(8)Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount 
Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn
School of Medicine at Mount Sinai, NY, USA.
(9)Department of Pathology, Molecular and Cell-based Medicine, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of
Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA.
(10)Department of Medicine, Hematology and Medical Oncology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School 
of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Human Immune
Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA.
(11)Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Department of Geriatrics and Palliative Medicine, Icahn School of 
Medicine at Mount Sinai, New York, NY, USA.
(12)Department of Microbiology, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Department of Pathology, Molecular and Cell-based Medicine, Icahn 
School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious
Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Global Health and Emerging Pathogen Institute, Icahn School of
Medicine at Mount Sinai, New York, NY, USA. Electronic address:
viviana.simon@mssm.edu.
(13)Department of Medicine, Hematology and Medical Oncology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School 
of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of
Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Electronic address: samir.parekh@mssm.edu.

DOI: 10.1016/j.ccell.2021.09.015 
PMCID: PMC8523488
PMID: 34706273  [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests The Icahn School of
Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer
as co-inventor. Viviana Simon and Carlos Cardo-Cordon are listed on the
serological assay patent application as co-inventors. Mount Sinai has spun out a 
company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has
consulted for Merck and Pfizer (before 2020) and is currently consulting for
Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal
models of SARS-CoV-2. Sundar Jagannath reports consulting fees from Bristol Myers
Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda
Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine.
Sacha Gnjatic reports past consultancy and/or advisory roles for Merck and
OncoMed and past or current research funding from Bristol-Myers Squibb,
Genentech, Boehringer-Ingelheim, Pfizer, Takeda, and Regeneron. Nina Bhardwaj
reports consultancy and/or advisory roles for Novartis, Apricity, Rome
Therapeutics, CureVac, Genotwin, BioNTech, Gildea, Tempest Therapeutics,
Boehringer Ingelheim, and Rubis Therapeutics. Other authors report no relevant
conflicts of interest.

